Concurrent chemoradiotherapy with nimotuzumab and capecitabine for patients with unresectable, postoperative residual, or recurrent gastric cancer: a prospective study

N. Lu,J. Jin,H. Ren,Y. Tamg,Xin Wamg,Liming Jiang,Ning Li,Yanru Feng,Shulian Wang,Weihu Wang,Yong-wen Song,Yueping Liu,H. Fang,Jiajia Zhang,Shuai Li,Yexiong Li

DOI: https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2016.05.008

2016-05-15

Abstract:Objective To investigate the adverse effects and short-term therapeutic effect of concurrent chemoradiotherapy with nimotuzumab and capecitabine for patients with unresectable, postoperative residual, or recurrent gastric cancer. Methods A prospective phase Ⅱ study was performed in patients with pathologically confirmed gastric cancer. Inclusion criteria were as follows: unresectable, postoperative residual, or recurrent gastric cancer in which lesions could be measured; lesions which could receive radiotherapy; expected survival time>3 months. All patients received intensity-modulated radiotherapy (54 Gy in 30 fractions for planned gross tumor volume, 45 Gy in 25 fractions for the prophylactic area in lymph nodes) and concurrent capecitabine (1 600 mg/m2 per day for 35 days) and nimotuzumab (200 mg once a week). Common Terminology Criteria for Adverse Events, version 3.0 and Response Evaluation Criteria in Solid Tumors were used to evaluate acute adverse effects and short-term therapeutic effect. Results A total of 30 patients were enrolled from 2010 to 2013. The median age was 57 years (range 35-66 years). There were 23 patients with postoperative residual or recurrent gastric cancer and 7 with unresectable gastric cancer. Twenty-eight patients received chemotherapy before being enrolled in this study and achieved stable disease or progression. During concurrent chemoradiotherapy, 5 patients (17%) experienced grade 3 acute adverse events, mainly thrombocytopenia (10%). At one month after treatment, the in-field objective response rate and stable disease rate were 43%(complete response 4%, partial response 39%) and 50%, respectively, and the systemic objective response rate and stable disease rate were 32% and 43%, respectively. Conclusions In patients with unresectable, postoperative residual, or recurrent gastric cancer, concurrent chemoradiotherapy with nimotuzumab and capecitabine has good safety, tolerability, short-term therapeutic effect, and in-field control. Clinical Trial Registry ClinicalTrials.gov, registration number: NCT01180166. Key words: Gastric neoplasms/radiochemotherapy; Radiochemotherapy, concurrent; Nimotuzumab; Capecitabine; Toxicity; Short-term effects

Medicine